ArticleInternational journal of women's health2025
The Sensitive Genes for Cervical Cancer: Two-Sample Mendelian Randomization with Experimental Validation.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Association and interaction network analysis of immune cell subgroups in cervical cancer microenvironment based on Mendelian randomization.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer, the fourth leading cause of female cancer mortality globally, faces treatment limitations due to drug resistance and few therapeutic options. This study seeks to identify novel therapeutic targets to address this urgent clinical need. Methods: Our team identified differentially expressed genes (DEGs) in cervical cancer using gene expression omnibus (GEO) datasets. Subsequently, Mendelian randomization (MR) analysis identified causal gene-cancer relationships, followed by enrichment analysis and The Cancer Genome Atlas (TCGA) validation. Finally, we further validated the functions of the selected target genes in cervical cancer cells and analyzed their Gene Set Enrichment Analysis (GSEA) results, drug sensitivity, and prognostic value. Results: We identified 2,801 upregulated and 1,646 downregulated DEGs. MR analysis identified 21 key cervical cancer-associated genes (14 upregulated, 7 downregulated), with TCGA validation confirming significant differential expression patterns. Among them, few studies have examined these core genes, particularly MERTK and SERPINF1, in cervical cancer. Experiments showed that MERTK and SERPINF1 play a role in cervical cancer. These genes help cancer cells grow, spread, and invade surrounding tissue. Mechanistically, MERTK regulates immune infiltration, whereas SERPINF1 modulates chromosomal activity. Clinically, SERPINF1 enhances overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in individuals with cervical cancer. Moreover, we discovered that several commonly used drugs for cervical cancer treatment, like paclitaxel, showed high efficacy against MERTK and SERPINF1. Conclusion: Our study uncovers MERTK and SERPINF1 as critical regulators of cervical cancer progression and survival, offering mechanistic insights into their roles in tumor behavior and the immune microenvironment. These findings provide a foundation for precision therapies, with SERPINF1 restoration and MERTK inhibition as promising strategies. Clinical translation of these targets could address current treatment limitations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.